$TPIA
Mycotopia Therapies Inc

2024 Q1 Form 10-Q Financial Statement

#000109690624001146 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $249.00 $998.00
YoY Change 1.22% -0.3%
% of Gross Profit
Operating Expenses $360.9K
YoY Change 148.86%
Operating Profit -$360.9K
YoY Change 148.86%
Interest Expense $65.07K
YoY Change -58.81%
% of Operating Profit
Other Income/Expense, Net -$65.07K
YoY Change -58.81%
Pretax Income -$425.9K
YoY Change 40.57%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$425.9K
YoY Change 40.57%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 14.90M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $370.4K $279.1K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $500.00 $0.00
Receivables
Other Receivables
Total Short-Term Assets $370.9K $279.1K
YoY Change 3.89% -27.67%
LONG-TERM ASSETS
Property, Plant & Equipment $249.00 $498.00
YoY Change -66.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.774M $1.940M
YoY Change 141817.76% 129597.79%
TOTAL ASSETS
Total Short-Term Assets $370.9K $279.1K
Total Long-Term Assets $1.774M $1.940M
Total Assets $2.145M $2.219M
YoY Change 498.67% 472.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $295.4K $239.7K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.599M $4.248M
YoY Change 196.22% 455.61%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.599M $4.248M
Total Long-Term Liabilities
Total Liabilities $4.599M $4.248M
YoY Change 196.22% 232.18%
SHAREHOLDERS EQUITY
Retained Earnings -$9.387M -$8.961M
YoY Change 16.14% 59.98%
Common Stock $14.90K $14.90K
YoY Change 0.27% 0.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.454M -$2.028M
YoY Change
Total Liabilities & Shareholders Equity $2.145M $2.219M
YoY Change 498.67% 472.91%

Cashflow Statement

Concept 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$425.9K
YoY Change 40.57%
Depreciation, Depletion And Amortization $249.00 $998.00
YoY Change 1.22% -0.3%
Cash From Operating Activities -$73.71K
YoY Change 155.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $165.0K
YoY Change
NET CHANGE
Cash From Operating Activities -$73.71K
Cash From Investing Activities $0.00
Cash From Financing Activities $165.0K
Net Change In Cash $91.29K
YoY Change -416.19%
FREE CASH FLOW
Cash From Operating Activities -$73.71K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-56022
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Mycotopia Therapies, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0645794
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
18851 NE 29th Ave.
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Aventura
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33180
CY2024Q1 dei City Area Code
CityAreaCode
954
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
233-3511
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14896791 shares
CY2024Q1 us-gaap Cash
Cash
370425 usd
CY2023Q4 us-gaap Cash
Cash
279134 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
500 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
370925 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
279134 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
249 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
498 usd
CY2024Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1773723 usd
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1939781 usd
CY2024Q1 us-gaap Assets
Assets
2144897 usd
CY2023Q4 us-gaap Assets
Assets
2219413 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
390714 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
341358 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
295435 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
239714 usd
CY2024Q1 fil Accrued Expenses Related Party
AccruedExpensesRelatedParty
648000 usd
CY2023Q4 fil Accrued Expenses Related Party
AccruedExpensesRelatedParty
576000 usd
CY2024Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1100000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1090651 usd
CY2024Q1 fil Due To Related Parties
DueToRelatedParties
165000 usd
CY2023Q4 fil Due To Related Parties
DueToRelatedParties
0 usd
CY2024Q1 fil Shareholder Loan
ShareholderLoan
2000000 usd
CY2023Q4 fil Shareholder Loan
ShareholderLoan
2000000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
4599148 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4247723 usd
CY2024Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
5000000 shares
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
5000000 shares
CY2024Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2024Q1 fil Liquidation Preference
LiquidationPreference
0 usd
CY2023Q4 fil Liquidation Preference
LiquidationPreference
0 usd
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14896791 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14896791 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14896791 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14896791 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
14897 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
14897 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6917774 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6917774 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9386923 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8960981 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2454252 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2028310 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2144897 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2219413 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
360872 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
145011 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
360872 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
145011 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-360872 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-145011 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
65070 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
157993 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-65070 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-157993 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-425942 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-303004 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-425942 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-303004 usd
CY2024Q1 fil Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.03
CY2023Q1 fil Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.02
CY2024Q1 fil Average Number Of Common Share Outstanding Basic And Diluted
AverageNumberOfCommonShareOutstandingBasicAndDiluted
14896791 shares
CY2023Q1 fil Average Number Of Common Share Outstanding Basic And Diluted
AverageNumberOfCommonShareOutstandingBasicAndDiluted
14858357 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2028310 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-425942 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2454252 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-891348 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-303004 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1194352 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-425942 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-303004 usd
CY2024Q1 us-gaap Depreciation
Depreciation
249 usd
CY2023Q1 us-gaap Depreciation
Depreciation
246 usd
CY2024Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
166058 usd
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
0 usd
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
9349 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
135616 usd
CY2024Q1 fil Increase In Prepaid Expenses
IncreaseInPrepaidExpenses
-500 usd
CY2023Q1 fil Increase In Prepaid Expenses
IncreaseInPrepaidExpenses
0 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
49356 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
43894 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-55721 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-22376 usd
CY2024Q1 fil Increase Decrease In Accrued Expenses Related Party
IncreaseDecreaseInAccruedExpensesRelatedParty
72000 usd
CY2023Q1 fil Increase Decrease In Accrued Expenses Related Party
IncreaseDecreaseInAccruedExpensesRelatedParty
72000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-73709 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28872 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
165000 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
165000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
91291 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-28872 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
279134 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
385899 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
370425 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357027 usd
CY2024Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2023Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-425942 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-73709 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
370925 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4599149 usd
CY2024Q1 fil Working Capital
WorkingCapital
4228224 usd
CY2024Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF"><b><i>Basis of Presentation</i></b></span></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF"> </span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;text-align:justify">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. We believe that the disclosures contained in these condensed financial statements are adequate to make the information presented herein not misleading. These condensed financial statements should be read in conjunction with the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC. The accompanying condensed financial statements are unaudited, but in the opinion of management contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of March 31, 2024, and the results of its operations and its cash flows for the three months ended March 31, 2024 and 2023. The balance sheet as of December 31, 2023 is derived from the Company’s audited financial statements. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2024.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MYC and NPD. All inter-company accounts and transactions have been eliminated in consolidation.</span></p>
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF"><b><i>Use of Estimates</i></b></span></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF"> </span></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF">The preparation of financial statements in conformity with U.S GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Our financial statements include, when applicable, disclosures of estimates, assumptions, uncertainties, and markets that could affect our financial statements and future operations.</span></p>
CY2024Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q1 us-gaap Depreciation
Depreciation
249 usd
CY2023Q4 us-gaap Depreciation
Depreciation
246 usd
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF"><b><i>Prior period reclassifications</i></b></span></p> <p style="font:13.5pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify"><span style="font-size:10pt">We have reclassified certain amounts in prior periods to conform with current presentation. Increase in accrued interest, and increase in accrued expenses – related party, in the amounts of $22,376 and $72,000, respectively, which were reported within increase in accounts payable and accrued expenses at March 31, 2023, have been reclassified on the statement of cash flows. </span></p>
CY2023Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-22376 usd
CY2023Q1 fil Increase Decrease In Accrued Expenses Related Party
IncreaseDecreaseInAccruedExpensesRelatedParty
72000 usd
CY2024Q1 fil Intangible Assets Acquired Through Promise To Issue Shares
IntangibleAssetsAcquiredThroughPromiseToIssueShares
2000000 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
226277 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
60219 usd
CY2024Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1773723 usd
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1939781 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
501825 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
666058 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
605839 usd
CY2024Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1773723 usd
CY2024Q1 fil Due To Related Parties
DueToRelatedParties
165000 usd
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
648000 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
576000 usd
CY2024Q1 fil Consulting Fee
ConsultingFee
288000 usd
CY2024Q1 fil Convertible Debt Outstanding
ConvertibleDebtOutstanding
1560435 usd
CY2024Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1265000 usd
CY2024Q1 fil Convertible Debt Interest
ConvertibleDebtInterest
295435 usd
CY2023Q4 fil Convertible Debt Outstanding
ConvertibleDebtOutstanding
1339714 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1100000 usd
CY2023Q4 fil Convertible Debt Interest
ConvertibleDebtInterest
239714 usd
CY2024Q1 fil Aggregate Debt Discount
AggregateDebtDiscount
0 usd
CY2023Q1 fil Aggregate Debt Discount
AggregateDebtDiscount
0 usd
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
9349 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
135616 usd
CY2024Q1 fil Unamortized Debt Discount
UnamortizedDebtDiscount
0 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14896791 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14896791 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14896791 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14896791 shares
CY2024Q1 fil Common Stock Issued To Settle Accounts Payable And Accrued Expenses
CommonStockIssuedToSettleAccountsPayableAndAccruedExpenses
43750 usd
CY2024Q1 fil Initial Net Carrying Value Of Mezzanine Equity
InitialNetCarryingValueOfMezzanineEquity
50000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1980039 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.93
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y3M10D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 fil Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
0 pure
CY2023Q1 fil Common Stock Issued On Cashless Exercise Of Warrant Shares
CommonStockIssuedOnCashlessExerciseOfWarrantShares
0 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1980039 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.93
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y10D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
666666 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.5
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y9M18D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2024Q1 fil Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
0 pure
CY2024Q1 fil Common Stock Issued On Cashless Exercise Of Warrant Shares
CommonStockIssuedOnCashlessExerciseOfWarrantShares
0 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
666666 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.5
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y6M18D

Files In Submission

Name View Source Status
0001096906-24-001146-index-headers.html Edgar Link pending
0001096906-24-001146-index.html Edgar Link pending
0001096906-24-001146.txt Edgar Link pending
0001096906-24-001146-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tpia-20240331.htm Edgar Link pending
tpia-20240331.xsd Edgar Link pending
tpia_ex31z1.htm Edgar Link pending
tpia_ex32z1.htm Edgar Link pending
tpia-20240331_cal.xml Edgar Link unprocessable
tpia-20240331_def.xml Edgar Link unprocessable
tpia-20240331_htm.xml Edgar Link completed
tpia-20240331_lab.xml Edgar Link unprocessable
tpia-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable